VIM and cancer: Since vimentin, a stromal intermediate filament protein is highly expressed during EMT, antibodies against cell-surface vimentin (CSV), a cancer-specific antigen, have been used to detect live CTCs in patients with EMT-associated carcinoma or malignant sarcomas [56,57,58,59].